Samsung Biologics posts Q2 2026 revenue of KRW 1,321 billion

Operating profit reached KRW 586 billion as the CDMO said it remained on track for the upper end of its 2026 guidance while expanding capacity, global offices and innovation investments.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.